CIK 0001984086 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Septerna, Inc.
Sign in to watch- Ticker
- SEPN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843891440
- Phone
- 650-338-3533
- Business address
- 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,210,085
- in 3 filings, $4.2M under 10b5-1 plans
Net −$4,210,085. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-11 | Bhatt Elizabeth President and COO | Option exercise 10b5-1 | +6,319 | $2.76 | $17K | 199,209 |
| 2026-08-11 | Bhatt Elizabeth President and COO | Sale 10b5-1 | −25,000 | $44.00 | $1.1M | 174,209 |
| 2026-08-11 | Bhatt Elizabeth President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,681 | 62,230 | ||
| 2026-08-11 | Bhatt Elizabeth President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,319 | 82,332 | ||
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +1,816 | $2.76 | $5K | 98,228 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +1,518 | $2.76 | $4K | 99,746 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −1,000 | $33.98 | $34K | 98,746 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −2,334 | $34.68 | $81K | 96,412 |
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,816 | 5,227 | ||
| 2026-08-03 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,518 | 12,418 | ||
| 2026-07-15 | Bhatt Elizabeth President and COO | Option exercise 10b5-1 | +4,000 | $6.81 | $27K | 178,209 |
| 2026-07-15 | Bhatt Elizabeth President and COO | Sale 10b5-1 | −4,000 | $33.99 | $136K | 174,209 |
| 2026-07-15 | Bhatt Elizabeth President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 80,911 | ||
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +3,333 | $2.76 | $9K | 99,745 |
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −2,100 | $34.10 | $72K | 97,645 |
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −1,233 | $34.81 | $43K | 96,412 |
| 2026-07-01 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,333 | 7,043 | ||
| 2026-06-29 | Shaikhly Samira Chief People Officer | Option exercise 10b5-1 | +2,178 | $6.81 | $15K | 2,971 |
| 2026-06-29 | Shaikhly Samira Chief People Officer | Sale 10b5-1 | −2,178 | $35.18 | $77K | 793 |
| 2026-06-29 | Shaikhly Samira Chief People Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,178 | 20,865 |
Page 2 of 8 · 148 trades